KW KOSEF 200 Futures Inverse 2X ETF (253230)

Overview

Patrys Limited is an innovative biotechnology company based in Melbourne, Australia, dedicated to the development and commercialization of novel antibody technologies aimed at treating cancer. The company, established in 2006, operates with a focus on creating advanced therapeutic options for patients suffering from primary and secondary brain cancers, metastases associated with NETosis, and other forms of the disease. Leveraging its proprietary technology, Patrys is at the forefront of developing treatments that can potentially transform cancer care, particularly for conditions that are currently difficult to treat with existing therapies.

Products and Services

• Deoxymab 3E10 (PAT-DX1)

This leading-edge treatment is being developed by Patrys to target primary and secondary brain cancers and metastases linked to NETosis. Its innovative mechanism allows it to be used either as a standalone treatment or in conjunction with traditional DNA damaging agents, including radiation and various chemotherapy drugs. Deoxymab 3E10 represents a significant leap forward in the company's commitment to targeting cancer through novel pathways.

• PAT-DX3

A full-sized antibody that carries over the DNA-targeting capabilities of PAT-DX1 but boasts distinct pharmacologic properties that may offer broader therapeutic advantages. PAT-DX3 is engineered to achieve unique tissue distribution and pharmacokinetic profiles. This diversification in Patrys’ product pipeline underscores the company's continuous effort to expand its range of cancer-fighting therapies, capitalizing on the foundational science behind PAT-DX1 to reach a wider array of cancer types.